Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
What happened
Shares of
Ziopharm Oncology (NASDAQ:ZIOP) were jumping 10.8% higher as of 11:55 a.m. EST on Friday. The solid gain came after the company provided its fourth-quarter update following the market close on Thursday.
Ziopharm announced a net loss in the fourth quarter of $22.8 million, or $0.11 per share. There were two bigger stories, though. The U.S. Food and Drug Administration (FDA) gave a green light for Ziopharm to begin testing its experimental T cell receptor-engineered T cell (TCR-T) therapies in phase 1/2 clinical studies. Also, Laurence Cooper is stepping down as CEO with board member Heidi Hagen taking his place as interim CEO.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors
ZIOPHARM Oncology IncFebruary 5, 2021 GMT
BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and long-term shareholder of Ziopharm.
James Huang, Chairman of the Board, said, “We welcome Bob to Ziopharm’s Board of Directors. With his experience and financial acumen, Bob will make an immediate contribution to Ziopharm and I believe the Board is now well positioned to partner with the management team to deliver on our very promising T-cell directed and cytokine technologies and opportunities.”